Background: Egypt is considered a region of the intermediate prevalence of hepatitis B virus (HBV) infection (4.5%). Seroprotection is assured when hepatitis B surface antibody (HBsAb) levels are ≥ 10 mIU/mL. Our study aimed to evaluate and compare the long-term immunogenicity and efficacy of the recombinant hepatitis B (HB) vaccine.

Methods: A cross-sectional study was done for children aged from 9 months to 15 years, receiving health care at Assiut University Children's Hospital, Assiut, Egypt in 3 months. HBsAb was quantitatively determined by enzyme-linked immune sorbent assay (ELISA).

Results: Seroprotection in infants less than 1 year was 89.7% with 55.2% having titer > 100 mIU/mL and this percent dropped to 64.4% after the first year of age with only 29% having titer > 100 mIU/mL. The overall protection percentage was 32.5% (> 100 mIU/mL), 34.7% of children showed levels between 10 and 100 mIU/mL, while 32.8% were less than 10 mIU/mL. Patients with diabetes mellitus were found to have the lowest seroprotective levels (83.3% were not protected). Non-protective levels were also detected in patients with malnutrition (55.6%), congenital heart diseases (43.2%) and chronic liver diseases (57.1%).

Conclusion: Our study shows failure to achieve satisfactory seroprotective levels for hepatitis B vaccine in both healthy and diseased children who adopted vaccination schedule in Upper Egypt. Booster dose in the second year of life is recommended for all children, particularly for those with diabetes millets, congenital heart disease and malnutrition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040530PMC
http://dx.doi.org/10.14740/gr636eDOI Listing

Publication Analysis

Top Keywords

100 miu/ml
16
recombinant hepatitis
8
hepatitis vaccine
8
upper egypt
8
titer 100
8
seroprotective levels
8
congenital heart
8
miu/ml
6
hepatitis
5
children
5

Similar Publications

Article Synopsis
  • The study assessed the effectiveness of a booster HBV vaccine in Italian medical students, revealing that a significant portion had low antibody levels after 15 years.
  • Out of 625 students, 355 were given a booster, and 92.77% of those who received it achieved adequate antibody levels after one month.
  • Results showed that physical activity improved immune response to the booster, highlighting the importance of maintaining higher pre-booster antibody levels for better vaccine effectiveness.
View Article and Find Full Text PDF

A blastocyst's implantation potential is linked to its originating oocyte cohort's blastulation rate: evidence for a cohort effect.

Fertil Steril

December 2024

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, California.

Objective: To investigate if blastocysts originating from different follicular cohorts have variable implantation rates, adjusted for oocyte age, morphology, and/or ploidy.

Design: Retrospective cohort.

Setting: Academic center.

View Article and Find Full Text PDF

Purpose: To investigate the relationship between early serum hCG levels after frozen embryo transfer and fetal anomalies.

Methods: This was a case-control study at a single academic fertility center between 1/2010 and 12/2021, including all patients who underwent euploid frozen embryo transfers resulting in any fetal anomaly confirmed at the time of induced abortion > 10 weeks or any anomaly reported at delivery. Controls included patients with healthy live births matched for age and day/grade of embryo after euploid FET.

View Article and Find Full Text PDF

Importance: Nonresponse to hepatitis B vaccine is common among people with HIV, resulting in vulnerability to infection with hepatitis B virus (HBV).

Objective: To compare the seroprotection response achieved with a 2-dose (noninferiority, 10% margin) and a 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) vs a conventional 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine) in people with HIV and prior nonresponse to HepB-alum vaccine.

Design, Setting, And Participants: This phase 3, open-label, randomized clinical trial included people with HIV receiving antiretroviral therapy (CD4 cell count ≥100 cells/μL and HIV RNA <1000 copies/mL) without past or present serological evidence of having HBV or a response to hepatitis B vaccine.

View Article and Find Full Text PDF

Gestational trophoblastic disease is a group of pregnancy-related trophoblastic tumours. Gestational trophoblastic neoplasia refers to its invasive and malignant forms: invasive mole, choriocarcinoma, placental site trophoblastic tumour and epithelioid trophoblastic tumour. Patients exhibit elevated beta human chorionic gonadotropin (β hCG) levels, sometimes exceeding 100 000 mIU/mL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!